We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

A novel epigenetic blood test to monitor minimal residual disease in high-risk neuroblastoma.

Petrie, K., et. al.,
Cancer Research

April 6, 2013

http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-87

Breast cancer: development of early non-invasive diagnostics to reduce disease mortality and psychological outcomes.

Jeznach, M., et.al.,
Psychoonkologia

February 3, 2013

http://www.termedia.pl/Breast-cancer-development-of-early-non-invasive-diagnostics-to-reduce-disease-mortality-and-psychological-outcomes,63,21815,0,1.html